An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Overview of attention for article published in New England Journal of Medicine, June 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 130 news outlets
blogs: 16 blogs
policy: 2 policy sources
twitter: 554 X users
patent: 36 patents
facebook: 16 Facebook pages

wikipedia: 9 Wikipedia pages
reddit: 9 Redditors
f1000: 1 research highlight platform
guideline: 6 clinical guideline sources
bluesky: 1 Bluesky user

Readers on

mendeley: 1040 Mendeley

So far, Altmetric has seen 182 news stories from 130 outlets.

Il diabete tipo 1 non comincia con la prima insulina: siamo pronti a cercarlo prima?

Il mio diabete, 30 Sep 2026

Bambino e madre dialogano con una professionista sanitaria sullo screening precoce del diabete tipo 1, con una rappresentazione…

Typ-I-Diabetes : Heilung in Sicht

Spektrum, 28 Sep 2026

Erstmals lässt sich Typ-I-Diabetes bereits im Vorstadium beeinflussen: Teplizumab kann den Krankheitsausbruch verzögern.

Accu-Chek Guide von Roche - Praxistaugliches Blutzucker-Messgerät im Alltagstest

Ad Hoc News, 08 Jul 2026

Verantwortlich: Nora Steinfeld, ad hoc news Fachredaktion Zubehoer

NICE recommends first drug to delay symptoms of type 1 diabetes for NHS use

Pharmaceutical Journal, 23 Jun 2026

The National Institute for Health and Care Excellence (NICE) has recommended the first drug to delay the onset of symptomatic…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 178 additional news stories.